Marshall Wace, LLP Adaptimmune Therapeutics PLC Transaction History

Marshall Wace, LLP

$72.2 Billion
Q2 2024

A detailed history of Marshall Wace, LLP transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 144,880 shares of ADAP stock, worth $141,982. This represents 0.0% of its overall portfolio holdings.

Number of Shares

144,880

Previous 254,013 42.96%

Holding current value

$141,982

Previous $401,000 64.84%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.83 - $1.47 $90,580 - $160,425	-109,133 Reduced 42.96%	144,880 $141,000
Q1 2024 May 15, 2024	BUY	$0.7 - $1.75 $177,809 - $444,522	254,013 New	254,013 $401,000
Q2 2023 Aug 14, 2023	BUY	$0.9 - $1.51 $245,412 - $411,748	272,681 New	272,681 $250,000
Q4 2022 Feb 14, 2023	BUY	$1.05 - $2.53 $93,629 - $225,602	89,171 New	89,171 $130,000
Q1 2022 May 16, 2022	SELL	$1.73 - $4.06 $982,287 - $2.31 Million	-567,796 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.5 - $5.68 $3.45 Million - $5.6 Million	-986,004 Reduced 63.46%	567,796 $2.13 Million
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $5.35 Million - $9.9 Million	1,553,800 New	1,553,800 $8.03 Million
Q3 2020 Nov 16, 2020	SELL	$7.66 - $10.78 $2.88 Million - $4.06 Million	-376,340 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$2.58 - $12.1 $970,957 - $4.55 Million	376,340 New	376,340 $3.77 Million
Q1 2020 May 15, 2020	SELL	$1.2 - $4.52 $34,922 - $131,541	-29,102 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$0.72 - $1.43 $36,105 - $71,708	-50,146 Reduced 63.28%	29,102 $35,000
Q3 2019 Nov 14, 2019	BUY	$1.43 - $3.81 $113,324 - $301,934	79,248 New	79,248 $120,000
Q1 2019 May 14, 2019	SELL	$3.63 - $6.06 $472,081 - $788,103	-130,050 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.76 - $14.16 $488,988 - $1.84 Million	130,050 New	130,050 $748,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

152M

Call Options Held

78.5K

Put Options Held

36.5K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $160M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Adaptimmune Therapeutics PLC Transaction History